FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.
Therapy Area
WHO calls for Phase III Ervebo vaccine trial amid Bundibugyo Ebola outbreak
BioVie stock sinks on Phase IIb Parkinson’s trial data
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
UK Prime Minister to meet with brain cancer patient after research appeal
Otsuka’s Voyxact stabilised kidney function at two years in Phase III IgAN trial
Schizophrenia “non-responders” may need more time, study finds
